India's Dr. Reddy's Laboratories Buys U.K. Dow Chemical Drug Units To Bolster Contract Research
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's second biggest generic drug firm, Reddy's Laboratories, bought two small molecule plants from a U.K. unit of Dow Chemical as part of a drive to gain technology to expand its contract manufacturing business